Key result
Primary prevention statin initiation linked to ~1.7% lower all-cause mortality in type 1 diabetes.
Why the study?
There is no consensus on using statins for primary prevention of cardiovascular disease and all-cause mortality in adults with type 1 diabetes due to lack of exclusive randomized controlled trials.
Does statin initiation reduce all-cause mortality and major cardiovascular disease in adults with Type 1 Diabetes for primary prevention?
Observational (n=20,880)
Yes
Does statin initiation reduce all-cause mortality and major cardiovascular disease in adults with Type 1 Diabetes for primary prevention?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Among adults with T1DM, statin initiation for primary prevention was associated with reductions in all-cause mortality and major CVD with a very low risk of adverse effects.”
“Despite well established benefits of statins in people with type 2 diabetes, the role of statins in type 1 diabetes (T1DM), particularly for primary prevention, has remained uncertain. Guidelines have extrapolated evidence from broader populations, leading to inconsistent recommendations and uneven uptake, especially among younger patients. Randomized controlled trials (RCTs), the criterion standard for establishing causal effects of treatments, have not been conducted specifically in this population. In the absence of trial data, observational studies have attempted to fill the void, but many have been limited by methodologic flaws and susceptibility to bias. In this issue of JACC, Blais et al bring new clarity through a rigorous target trial emulation (TTE), using UK primary care data to estimate the long-term effectiveness and safety of statins for primary prevention in adults with T1DM.”
Statin initiation for primary prevention in adults with Type 1 Diabetes is associated with significant reductions in all-cause mortality and major cardiovascular disease, with a very low risk of adverse effects.
BACKGROUND There is no consensus for using statins for primary prevention of cardiovascular disease (CVD) and all-cause mortality in adults with type 1 diabetes mellitus (T1DM), because no randomized controlled trial has exclusively investigated statins in this population. OBJECTIVES In this study, the authors sought to evaluate the long-term risks and benefits of statins for primary prevention in adults with T1DM. METHODS We performed a sequential target trial emulation comparing statin initiation vs noninitiation using UK primary care data from the IQVIA Medical Research Data database. Persons aged 25 to 84 years with a diagnosis record of T1DM with prescription of insulin from January 2005 to December 2016 were included if they had baseline low-density lipoprotein-cholesterol (LDL-C) ≥2.6 mmol/L (100 mg/dL) or non-high-density lipoprotein cholesterol ≥3.4 mmol/L (130 mg/dL). Persons with preexisting coronary artery disease, myocardial infarction, stroke, heart failure, myopathy, liver disease, rheumatic heart disease, schizophrenia or cancer were excluded. Main outcome measures were all-cause mortality, major CVD and adverse events (myopathy and liver dysfunction). We estimated 10-year absolute risk differences (RDs) for the observational analogues of the intention-to-treat (ITT) and per-protocol (PP) effects. RESULTS We included 4,176 statin initiator (mean age of 45 years, 33.1% <40 years, 40.6% female) and 16,704 noninitiator person-trials with median follow-up of 6 years. Compared with noninitiation, statins were associated with reductions in all-cause mortality (RDITT: -1.66% [95% CI: -2.79% to -0.45%]; RDPP: -3.48% [95% CI: -4.68% to -2.07%]) and major CVD (RDITT: -1.63% [95% CI: -2.57% to -0.53%]; RDPP: -2.69% [95% CI: -4.00% to -1.22%]). Some analyses suggested a slight association with increased risk of liver dysfunction but no association with myopathy. In subgroup analyses, absolute risk reductions were generally larger in women, persons ≥40 years of age, persons with baseline LDL-C ≥3.4 mmol/L (130 mg/dL), and persons with a higher predicted cardiovascular risk. CONCLUSIONS Among adults with T1DM, statin initiation for primary prevention was associated with reductions in all-cause mortality and major CVD with a very low risk of adverse effects. The differences in absolute risk reductions can help guide personalized statin treatment decisions in T1DM.
No takes yet. Share an insight, caveat, or question.
Blais et al. (2025) conducted an observational in Type 1 diabetes mellitus (n=20,880). Statins vs. Noninitiation was evaluated on All-cause mortality (RD -1.66%, 95% CI -2.79 to -0.45). Statin initiation for primary prevention in adults with type 1 diabetes was associated with reductions in all-cause mortality (RD -1.66%; 95% CI -2.79 to -0.45) and major CVD.
Synapse has enriched 5 related papers. Consider them for comparative context: